期刊文献+

维奈托克对急性髓系白血病肿瘤标志基因和炎症因子的影响 被引量:6

Effect of Venetoclax on Tumor Associated Genes and Cytokines in Acute Myeloid Leukemia
下载PDF
导出
摘要 目的观察维奈托克对急性髓系白血病(AML)外周血淋巴细胞RNA和炎症因子的影响。方法采用噻唑蓝(MTT)法检测维奈托克的最适浓度及AML细胞凋亡情况,实时定量聚合酶链反应检测维奈托克作用前后AML患者外周血免疫细胞标志mRNA的表达水平变化,酶联免疫吸附(ELISA)检测炎症因子的变化。结果 300 nmol·L-1维奈托克显著降低AML患者外周血单核细胞恶性肿瘤相关基因BCL-2、SIRPα、CD47、PDL-1、PDL-2、EZH2的表达(P<0.05或P<0.01),并促进免疫反应活化分子TRAIL和肿瘤坏死因子(TNF)-α的表达(P<0.01)。ELISA检测结果显示TNF-α和干扰素-γ释放量显著升高。结论维奈托克可以调控肿瘤相关基因并促进免疫细胞释放炎症因子,从而促进AML肿瘤细胞凋亡。 ObjectiveTo investigate the effect of venetoclax on RNA expression and cytokines release in lymphocytes isolated from acute myeloid leukemia(AML)patients.MethodsMTT method was performed to study the apoptosis of AML cells and optimize the concentration of venetoclax.The gene markers expression and cytokines production before and after venetoclax treatment were examined by RT PCR and ELISA methods,respectively.ResultsAfter chemotherapy,the expression of tumor associated inhibitory genes including BCL2(P<0.05),SIRPα(P<0.05),CD47(P<0.05),PDL1(P<0.05),PDL2(P<0.01),and EZH2(P<0.05)were significantly decreased when venetoclax reached300nmol·L-1.In addition,the expression levels of the activated molecules significantly increased,such as TRAIL(P<0.01)and TNF-α(P<0.01).The ELISA results showed that the release of human TNF-αand IFN-γhave significantly increased.ConclusionVenetoclax,which is a chemotherapeutic drug,can be used as tumor targeting drug.It can promote apoptosis in AML patients by regulating the genes expressions related to malignancy and cytokines production.
作者 赵爽 赵宏伟 马威 ZHAO Shuang;ZHAO Hongwei;MA Wei(Department of Pharmacy,the Fist Hospital of Jilin University ,Changchun 130021,China)
出处 《医药导报》 CAS 北大核心 2018年第1期31-34,共4页 Herald of Medicine
关键词 维奈托克 白血病 髓系 急性 基因 肿瘤相关 炎症因子 Venetoclax Leukemia,myeloid,acute Gene,tumor associate Cytokines
  • 相关文献

参考文献1

二级参考文献7

  • 1Marsters SA, Pitti RA, Sheridan JP, et al. Control of apoptosis signaling by Apo2 ligand. Recent Prog Horm Res, 1999; 54: 225 -234
  • 2Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer. Mol Cells,2003; 15(3) : 283 -293
  • 3Jeremias I, Herr I, Boehler T, et al. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol, 1998; 28 ( 1 ):143 - 152
  • 4Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem, 2000; 275(30): 23319-23325
  • 5Wen J, Ramadevi N, Nguyen D, et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood, 2000;96: 3900- 3906
  • 6Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol, 1998; 10:559-563
  • 7Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 1997; 7: 813-820

共引文献12

同被引文献28

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部